Cited by 385SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies

The DOI matches its Crossref record; 7 of the 8 references it cites were found in a registry or an index.

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Open access

Jangra, Sonia, Ye, Chengjin, Rathnasinghe, Raveen, Stadlbauer, Daniel, Alshammary, Hala, Amoako, Angela A., Awawda, Mahmoud H., Beach, Katherine F, Bermúdez-González, Maria C., Chernet, Rachel L., Eaker, Lily Q., Ferreri, Emily D., Floda, Daniel L., Gleason, Charles R., Kleiner, Giulio, Jurczyszak, Denise, Matthews, Julia C., Mendez, Wanni A., Mulder, Lubbertus C.F., Russo, Kayla T., Salimbangon, Ashley-Beathrese T., Saksena, Miti, Shin, Amber S., Sominsky, Levy A., Srivastava, Komal, Krammer, Florian, Simon, Viviana, Martinez-Sobrido, Luis, García-Sastre, Adolfo, Schotsaert, Michael·2021·The Lancet Microbe

DOI 10.1016/s2666-5247(21)00068-9PMC PMC8026167

Open this paper in CoChat — free account Open PDF

Abstract

It is concerning that emerging variants of SARS-CoV-2 can evade neutralising antibodies induced by previous infection or vaccination through mutations in the spike protein, including the receptor-binding domain (RBD). The asparagine (N) to tyrosine (Y) substitution at position 501 (N501Y), present in variants of concern belonging to the B.1.1.7, B.1.351, and P.1 lineages, does not seem to affect in-vitro neutralisation of human convalescent or post-vaccination sera. However, additional substitutions, such as E484K present in B.1.351 and P.1 lineages, might allow evasion from neutralising antibodies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s2666-5247(21)00068-9

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
(2021) · doi:10.1101/2021.01.15.426911 · Cited by 1,354
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419
The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human seraPreprint
Rathnasinghe, R., Jangra, S., Čupić, A., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., Mena, I., Vrieze, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.01.19.21249592 · Cited by 110
Self-citation

Show all 8 references

Sorted by citations

Items 201–300 of 385

Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042172 · Cited by 9
Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Mallik, B., Nandi, S. S., & Lee, S. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105282 · Cited by 10
Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses
Lim, H. T., Kok, B. H., Lim, C. P., Majeed, A. B. A., Leow, C. Y., & Leow, C. Y. (2022) · Biomedical Engineering Advances · doi:10.1016/j.bea.2022.100054 · Cited by 10
A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients
Eslami, S., Glassy, M. C., & Ghafouri‐Fard, S. (2021) · Gene · doi:10.1016/j.gene.2021.146113 · Cited by 12
SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
Gorshkov, K., Vasquez, D. M., Chiem, K., Ye, C., Tran, B. N., de la Torre, J. C., Moran, T. M., Chen, C. Z., Martínez‐Sobrido, L., & Zheng, W. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00182 · Cited by 10
Self-citation
COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10
Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine
Patel, R. S., & Agrawal, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952229 · Cited by 10
Higher Omicron JN.1 Coronavirus Transmission due to Unique 17MPLF Spike Insertion compensating 24LPP, 69HV, 145Y, 211N and 483V deletions in the spikePreprint
Chakraborty, A. K. (2024) · Research Square · doi:10.21203/rs.3.rs-3830998/v1 · Cited by 10
High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2
Bhadane, R. N., & Salo‐Ahen, O. M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10112779 · Cited by 10
Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions
Pham, L. V., Underwood, A. P., Binderup, A., Fahnøe, U., Fernandez-Antunez, C., Mendez, B. L., Ryberg, L. A., Galli, A., Sølund, C. S., Weis, N. M., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2412643 · Cited by 9
Antibody–nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants
Nguyen, H. V., & Li, M. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14263-1 · Cited by 9
Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine–Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019
Tang, J., Grubbs, G., Lee, Y., Wu, H., Luke, T. C., Egland, K. A., Bausch, C. L., Sullivan, E. J., & Khurana, S. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac031 · Cited by 9
The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals
Uwamino, Y., Yokoyama, T., Shimura, T., Nishimura, T., Sato, Y., Wakui, M., Kosaki, K., Hasegawa, N., & Murata, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.047 · Cited by 9
Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies
Chen, J., & Wei, G. (2022) · Communications in Information and Systems · doi:10.4310/cis.2022.v22.n3.a3 · Cited by 9
Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency
Markarian, N. M., Galli, G., Patel, D., Hemmings, M., Nagpal, P., Berghuis, A. M., Abrahamyan, L. G., & Vidal, S. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.933983 · Cited by 10
Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages
Tahsin, A., Ahmed, R., Bhattacharjee, P., Adiba, M., Saba, A. A., Yasmin, T., Chakraborty, S., Hasan, A. K. M. M., & Nabi, A. N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105903 · Cited by 9
Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles
Chang, X., Liu, X., Mohsen, M. O., Zeltiņš, A., Martina, B. E. E., Vogel, M., & Bachmann, M. F. (2022) · Vaccines · doi:10.3390/vaccines10020307 · Cited by 9
Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique CharacteristicsPreprint
Cao, W., Cho, C.-C. D., Geng, Z. Z., Ma, X. R., ALLEN, R. D., Shaabani, N., Vatansever, E. C., Alugubelli, Y. R., Ma, Y., Ellenburg, W. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.08.447613 · Cited by 9
Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
Álvarez-Díaz, D. A., Laiton‐Donato, K., Torres, O., Ruiz-Moreno, H. A., Franco-Muñoz, C., Beltran, M. A., Mercado, M., Rueda, M. G., & Muñoz, A. L. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198629 · Cited by 8
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection
Al-Hatamleh, M. A. I., Abusalah, M. A. H., Hatmal, M. M., Alshaer, W., Ahmad, S., Mohd-Zahid, M. H., Rahman, E. N. S. E. A., Yean, C. Y., Alias, I. Z., Uskoković, V., et al. (2022) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2022.11.007 · Cited by 8
Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection
Chen, J., Li, Y., & Liu, Z. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101249 · Cited by 8
Nanomedicine approaches against SARS-CoV-2 and variants
Zhang, H., Liu, Y., & Liu, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.004 · Cited by 8
Dynamic analysis of SARS-CoV-2 evolution based on different countries
Xiao, B., Wu, L., Sun, Q., Shu, C., & Hu, S. (2024) · Gene · doi:10.1016/j.gene.2024.148426 · Cited by 9
Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2
Girl, P., von Buttlar, H., Mantel, E., Antwerpen, M. H., Wölfel, R., & Müller, K. (2024) · Vaccines · doi:10.3390/vaccines12050515 · Cited by 8
Long-term serial passaging of SARS-CoV-2 reveals signatures of convergent evolution
Foster, C. S. P., Walker, G. J., Jean, T., Wong, M., Brassil, L., Isaacs, S. R., Lyu, Y., Turville, S. G., Kelleher, A. D., & Rawlinson, W. D. (2025) · Journal of Virology · doi:10.1128/jvi.00363-25 · Cited by 11
Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations
Pirnay, J., Selhorst, P., Hong, S. L., Cochez, C., Potter, B. I., Maes, P., Petrillo, M., Dudas, G., Claes, V., der Beken, Y. V., et al. (2021) · Viruses · doi:10.3390/v13071359 · Cited by 8
Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time
Moustafa, A. M., & Planet, P. J. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab051 · Cited by 8
Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines
Al-Zyoud, W. A., & Haddad, H. I. (2021) · Biochimie · doi:10.1016/j.biochi.2021.08.011 · Cited by 9
High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1
Bolland, W., Michel, V., Planas, D., Hubert, M., Guivel‐Benhassine, F., Porrot, F., Staropoli, I., N’Debi, M., Rodriguez, C., Fourati, S., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01351-23 · Cited by 8
Molecular epidemiology of SARS-CoV-2 in Northern South Africa: wastewater surveillance from January 2021 to May 2022
Tambe, L. A. M., Mathobo, P., Matume, N. D., Munzhedzi, M., Edokpayi, J. N., Viraragavan, A., Glanzmann, B., Tebit, D. M., Mavhandu-Ramarumo, L. G., Street, R. A., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1309869 · Cited by 7
The challenge of screening SARS-CoV-2 variants of concern with RT-qPCR: One variant can hide another
Blairon, L., Cupaiolo, R., Piteüs, S., Beukinga, I., & Tré‐Hardy, M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114248 · Cited by 7
Emergence of SARS-CoV-2 Variant B.1.575.2, Containing the E484K Mutation in the Spike Protein, in Pamplona, Spain, May to June 2021
Trobajo‐Sanmartín, C., Miqueleiz, A., Portillo, M. E., Fernández-Huerta, M., Navascués, A., Sara, P. S., Moreno, P. L., Ordoñez, G. R., Castilla, J., & Ezpeleta, C. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01736-21 · Cited by 7
Phylogenetic analysis of 17271 Indian SARS-CoV-2 genomes to identify temporal and spatial hotspot mutations
Ghosh, N., Nandi, S., & Saha, I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265579 · Cited by 7
Vaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
Liu, H., Aviszus, K., Zelarney, P. T., Liao, S., Gerber, A. N., Make, B. J., Wechsler, M. E., Marrack, P., & Reinhardt, R. L. (2023) · ERJ Open Research · doi:10.1183/23120541.00400-2023 · Cited by 7
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N. H., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51959-6 · Cited by 9
Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant
Ngô, S. T., Nguyen, T. H., Pham, D.-H., Tùng, N. T., & Nam, P. C. (2021) · RSC Advances · doi:10.1039/d1ra04134g · Cited by 7
Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South IndiaPreprint
Murugesan, M., Mathews, P., Paul, H. E., Rajiv Karthik, K., Mammen, J., & Rupali, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3914633 · Cited by 7
SARS-CoV-2 variants from COVID-19 positive cases in the Free State province, South Africa from July 2020 to December 2021
Mwangi, P. N., Okendo, J., Mogotsi, M. T., Ogunbayo, A. E., Adelabu, O. A., Sondlane, H., Maotoana, M. G., Mahomed, L., Morobadi, M. D., Vawda, S., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.935131 · Cited by 6
Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
Chang, X., Liu, X., Martina, B. E. E., Zeltiņš, A., Augusto, G. S., Vogel, M., Mohsen, M. O., Speiser, D. E., & Bachmann, M. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1114396 · Cited by 5
Wastewater sequencing as a powerful tool to reveal SARS-CoV-2 variant introduction and spread in French Guiana, South America
Combe, M., Chérif, E., Deremarque, T., Rivera‐Ingraham, G. A., Seck-Thiam, F., Justy, F., Doudou, J.-C., Carod, J.-F., Carage, T., Procureur, A., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.171645 · Cited by 6
A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines
Banerjee, S., Banerjee, D., Singh, A., & Saharan, V. A. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02247-3 · Cited by 6
Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection
Serrano, L., Algarate, S., Herrero‐Cortina, B., Bueno, J., González-Barriga, M. T., Ducons, M., Montero‐Marco, J., Acha, B., Taboada, A., Sanz-Burillo, P., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15699 · Cited by 4
Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
Almanza, G., Clark, A. E., Kouznetsova, V. L., Olmedillas, E., Castro, A., Tsigelny, I. F., Wu, Y., Gao, G. F., Leibel, S. L., Bray, W. A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010686 · Cited by 5
Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology
Zhou, Y., Wang, H., Li, Y., & Wang, Q. (2022) · Molecules · doi:10.3390/molecules27238257 · Cited by 6
Taking stock of the mutations in human SARS-CoV-2 spike proteins: From early days to nearly the end of COVID-19 pandemic
Guruprasad, L., Naresh, G. K. R. S., & Boggarapu, G. (2023) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2023.100107 · Cited by 7
Rural populations facilitated early SARS-CoV-2 evolution and transmission in Missouri, USA
Tang, C. Y., Li, T., Haynes, T., McElroy, J. A., Ritter, D. G., Hammer, R., Sampson, C. S., Webby, R. J., Hang, J., & Wan, X. (2023) · npj Viruses · doi:10.1038/s44298-023-00005-1 · Cited by 6
Characterization of the evolutionary and virological aspects of mutations in the receptor binding motif of the SARS-CoV-2 spike protein
Masuda, Y., Nasser, H., Zahradník, J., Mitoma, S., Shimizu, R., Nagata, K., Takaori‐Kondo, A., Schreiber, G., Shirakawa, K., Saito, A., et al. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1328229 · Cited by 6
Within-host evolution of SARS-CoV-2: how often are de novo mutations transmitted from symptomatic infections?
Korosec, C. S., Wahl, L. M., & Heffernan, J. M. (2024) · Virus Evolution · doi:10.1093/ve/veae006 · Cited by 6
A tool for the cheap and rapid screening of SARS-CoV-2 variants of concern (VoCs) by Sanger sequencing
Burgos, G., Ambuludí, A., Morales-Jadán, D., García-Bereguiain, M. Á., Muslin, C., Armijos‐Jaramillo, V., Carvajal, M., Muñoz, E. B., Guevara, R., Prado, B., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05064-22 · Cited by 5
Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infectionsPreprint
Monteil, V., Devignot, S., Klingström, J., Thålin, C., Kellner, M. J., Christ, W., Havervall, S., Mereiter, S., Knapp, S., Montserrat, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.25.474113 · Cited by 6
Dynamics of SARS-CoV-2 Seroprevalence in a Large US population Over a Period of 12 MonthsPreprint
Karkanitsa, M. L., Li, Y., Valenti, S., Spathies, J., Kelly, S., Hunsberger, S., Yee, L. M., Croker, J. A., Wang, J., Alfonso, A. L., et al. (2023) · medRxiv · doi:10.1101/2023.10.20.23297329 · Cited by 5
Human-to-dog Transmission of SARS-CoV-2 Lota Variant: Should COVID-19 Patients Avoid Close Contact with their Pets During Illness?Preprint
Rivero, R., Garay, E., Botero, Y., Serrano-Coll, H., Gastelbondo, B., Muñoz, M., Ballesteros, N., Castañeda, S., Patiño, L. H., Ramirez, J. D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-821033/v1 · Cited by 6
Spatiotemporal evolution and transmission dynamics of Alpha and Delta SARS-CoV-2 variants contributing to sequential outbreaks in Cambodia during 2021
Su, Y. C. F., Zeller, M. A., Ou, T. P., Ma, J., Pum, L., Zhang, R., Rath, S., Heang, V., Kol, S., Lim, R., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00685-7 · Cited by 6
Impact of SARS-CoV-2 RBM Mutations N501Y and E484K on ACE2 Binding: A Combined Computational and Experimental Study
Rombel‐Bryzek, A., Petkov, P., Lilkova, E., Ilieva, N., Litov, L., Kubus, M., & Witkowska, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094064 · Cited by 5
An Autochthonous Outbreak of the SARS-CoV-2 P.1 Variant of Concern in Southern Italy, April 2021
Loconsole, D., Sallustio, A., Centrone, F., Casulli, D., Ferrara, M. M., Sanguedolce, A., Accogli, M., & Chironna, M. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6030151 · Cited by 5
E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces
dos Santos, V. P., Rodrigues, A., Dutra, G. C. S., Bastos, L. L., Mariano, D., de Mendonça, J. G., Lobo, Y. J. G., Mendes, E. M. A. M., Maia, G. D. C. F., Machado, K., et al. (2022) · PeerJ · doi:10.7717/peerj.13099 · Cited by 5
Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity
Rizvi, F., Khan, M. A., Ansari, W. A., Ali, K., Khan, M. A., & Khan, M. A. (2023) · Coronaviruses · doi:10.2174/2666796704666230328171636 · Cited by 5
SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
Abduljaleel, Z., Melebari, S., Athar, M., Dehlawi, S., Kumar, S., Aziz, S. A. A., Dannoun, A., Malik, S. M., Thasleem, J., & Doss, C. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110798 · Cited by 5
Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India
Sarkar, R., Saha, R., Mallick, P., Sharma, R. P., Kaur, A., Dutta, S., & Chawla‐Sarkar, M. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.11.020 · Cited by 6
Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasionPreprint
Lin, X., Xue, W., Zhang, Y., Fu, B., Trimpert, J., Xing, N., Kunec, D., Tang, W., Xiao, Y., Meng, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.20.473471 · Cited by 6
Insights into the limited global spread of the immune evasive SARS-CoV-2 variant MuPreprint
Petrone, M. E., Lucas, C. G. D. O., Menasché, B. L., Breban, M. I., Yildirim, I. B., Campbell, M., Omer, S. B., Ko, A. I., Grubaugh, N. D., Iwasaki, A., et al. (2022) · medRxiv · doi:10.1101/2022.03.28.22273077 · Cited by 5
A Method of Identification of SARS-CoV-2 Variant Using NCBI BLAST-2 100% Homology Search with Specific Oligonucleotides Selected at the Deletion Boundaries of S, N, ORF7a, ORF8 and ORF1ab ProteinsPreprint
Chakraborty, A. K. (2022) · Research Square · doi:10.21203/rs.3.rs-2082525/v1 · Cited by 5
Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies
McIlroy, P. R., Pham, L. T. M., Sheffield, T. Y., Stefan, M. A., Thatcher, C. E., Jaryenneh, J. D., Schwedler, J. L., Sinha, A., Sumner, C. A., Jones, I. K. A., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012903 · Cited by 5
An Intranasal Nanomedicine Functions as Both Potent Broad‐spectrum Viral Inhibitor and Quasi‐Vaccine
Chen, J., Li, Y., Xiao, L., Guo, Z., Lu, W., Huang, J., Li, J., Li, B., & Liu, Z. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202501533 · Cited by 5
Unlocking the Power of Molecular Cloning: Revolutionizing Medical Microbiology Procedures
Datta, N. (2024) · University of Michigan Undergraduate Research Journal · doi:10.3998/umurj.5509 · Cited by 4
Redirecting a Broad-Spectrum Nanobody Against the Receptor-Binding Domain of SARS-CoV-2 to Target Omicron Variants
Intasurat, K., Submunkongtawee, N., Longsompurana, P., Thaiprayoon, A., Kasemsukwimol, W., Sirimanakul, S., Boonsilp, S., Seetaha, S., Choowongkomon, K., & Waraho‐Zhmayev, D. (2024) · Applied Sciences · doi:10.3390/app142210548 · Cited by 4
Current Therapeutic Strategies and Possible Effective Drug Delivery Strategies against COVID-19
Dastidar, D. G., Ghosh, D., Ghosh, S., & Chakrabarti, G. (2022) · Current Drug Delivery · doi:10.2174/1567201819666221004094509 · Cited by 4
Proven Novel Method to Curtail Covid-19 Pandemic, Long Covid, any Future Viral Pandemics, Including Influenza, Due to RNA/DNA Viruses Through Inactivation of their Naked RNA/DNA, and Hospital Acquired [Nosocomial] Infections
Reddy, M. S. (2023) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2023.16.000880 · Cited by 3
Spike-Seq: An amplicon-based high-throughput sequencing approach for the sensitive detection and characterization of SARS-CoV-2 genetic variations in environmental samples
Adamopoulos, P. G., Diamantopoulos, M. A., Boti, M. A., Zafeiriadou, A., Galani, A., Kostakis, M. G., Markou, A. N., Sideris, D. C., Avgeris, M., Τhomaidis, Ν. S., et al. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.169747 · Cited by 4
Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies
Müller, K., Girl, P., Giebl, A., Grützner, S., Antwerpen, M. H., Khatamzas, E., Wölfel, R., & von Buttlar, H. (2021) · Virus Genes · doi:10.1007/s11262-021-01871-8 · Cited by 4
Emergence of a new SARS-CoV-2 variant from GR clade with a novel S glycoprotein mutation V1230L in West Bengal, IndiaPreprint
Sarkar, R., Saha, R., Mallick, P., Sharma, R. P., Kaur, A., Dutta, S., & Chawla‐Sarkar, M. (2021) · medRxiv · doi:10.1101/2021.05.24.21257705 · Cited by 4
Direct Comparison of RT-ddPCR and Targeted Amplicon Sequencing for SARS-CoV-2 Mutation Monitoring in WastewaterPreprint
Lou, E. G., Sapoval, N., McCall, C., Bauhs, L., Carlson‐Stadler, R., Kalvapalle, P. B., Lai, Y., Palmer, K., Penn, R., Rich, W., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4022373 · Cited by 4
Spectroscopic secondary structure fingerprint of β-variant of SARS-CoV-2 spike glycoprotein
Mosetti, R., Mancini, T., Bertelà, F., Macis, S., Luchetti, N., Minicozzi, V., Lupi, S., & D’Arco, A. (2025) · European Biophysics Journal · doi:10.1007/s00249-025-01782-8 · Cited by 3
Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawai’i to facilitate public-health policies
Maison, D. P., Cleveland, S. B., & Nerurkar, V. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278287 · Cited by 3
A high-resolution melt curve toolkit to identify lineage-defining SARS-CoV-2 mutations
Fraser, A. J., Greenland-Bews, C., Kelly, D. F., Williams, C. T., LSTM Diagnostics Group, Bengey, D., Buist, K., Clerkin, K., Finch, L. S., Gould, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30754-1 · Cited by 3
Phylogeny and evolution of SARS-CoV-2 during Delta and Omicron variant waves in India
Singh, U. B., Deb, S., Rani, L., Gupta, R., Verma, S., Kumari, L., Bhardwaj, D., Bala, K., Ahmed, J., Gourav, S., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222832 · Cited by 6
SEQUENCE ANALYSIS OF HOT SPOT REGIONS OF SPIKE AND RNA‑DEPENDENT‑RNA POLYMERASE (RDRP) GENES OF SARS-COV-2 IN KERMAN, IRAN
--, N., Ramin, Ramezani, A., Farokhnia, M., & Sarvari, J. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.042 · Cited by 4
Whole-Genome Sequences of SARS-CoV-2 Lineage B.1.525 Strains (Variant η) Detected from Patients in the Abruzzo Region (Central Italy) during Spring 2021
Compagni, E. D., Mangone, I., Bonfini, B., Gennaro, A. D., Teodori, L., Leone, A., Casaccia, C., Portanti, O., Averaimo, D., Zilli, K., et al. (2021) · Microbiology Resource Announcements · doi:10.1128/mra.00618-21 · Cited by 3
Fast forward evolution in real time: the rapid spread of SARS-CoV-2 variant of concern lineage B.1.1.7 in Saxony-Anhalt over a period of 5 months
Glaß, M., Misiak, D., Misiak, C., Müller, S., Rausch, A., Angermann, K., Hoyer, M., Zabel, R., Kehlen, A., Möbius, B., et al. (2021) · Journal of Laboratory Medicine · doi:10.1515/labmed-2021-0092 · Cited by 3
α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
Zou, J., Jing, H., Zhang, X., Liu, Y., Zhao, Z., Duan, L., Yuan, Y., Chen, Z., Gou, Q., Xiong, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757691 · Cited by 3
In vitro neutralizing activity of BNT162b2 mRNA‐induced antibodies against full B.1.351 SARS‐CoV‐2 variant
Serrano‐Conde, E., Leyva, A., Fuentes, A. P., de Salazar, A., Chueca, N., Pérez‐Castro, S., Regueiro, B. J., Rojas, A., Mendoza, J., Rojas, J., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14417 · Cited by 3
Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants
Au, W. Y., Ye, C., Briner, S. L., Suarez, G. D., Han, J., Xu, X., Park, J., Brindley, M. A., Martínez‐Sobrido, L., & Cheung, P. P. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.02.030 · Cited by 3
Self-citation
Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper
Chotpitayasunondh, T., Fisher, D. A., Hsueh, P., Lee, P., Crespo, K. A. N., & Ruxrungtham, K. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030024 · Cited by 3
Análisis desde la academia del impacto en las dimensiones salud y economía por el covid-19 en el Ecuador
de Machala, U. T., Lee, A. J. C., de Machala, U. T., Abad, C. J. Q., & de Machala, U. T. (2023) · Editorial UTMACH eBooks · doi:10.48190/9789942241689 · Cited by 3
Spatiotemporal dissemination pattern of SARS-CoV-2 B1.1.28-derived lineages introduced into Uruguay across its southeastern border with BrazilPreprint
Rego, N., Fernández-Calero, T., Arantes, I., Noya, V., Mir, D., Brandes, M., Zanetti, J., Arleo, M., Pereira-Flores, E., Possi, T., et al. (2021) · medRxiv · doi:10.1101/2021.07.05.21259760 · Cited by 3
SARS-CoV-2 variants exhibit increased kinetic stability of open spike conformations as an evolutionary strategyPreprint
Yang, Z., Han, Y., Ding, S., Finzi, A., Mothes, W., & Lu, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.11.463956 · Cited by 3
SARS-CoV-2 Omicron Variant Wave in India: Advent, Phylogeny and EvolutionPreprint
Singh, U. B., Deb, S., Chaudhry, R., Bala, K., Rani, L., Gupta, R., Kumari, L., Ahmed, J., Gaurav, S., Perumalla, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.14.491911 · Cited by 3
Differential kinetics of SARS-CoV-2 proteases revealed by a two-color, BRET-based dual protease biosensor, DuProSense
Fatima, A., Geethakumari, A. M., Uddin, S. M. N., Philip, A. M., Sultana, A., Islam, Z., Aouida, M., Kolatkar, P. R., & Biswas, K. H. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118848 · Cited by 2
Analysing the Launch of COVID-19 Vaccine National Rollouts: Nine Case Studies
Gannon, J. R., Azari, R., Lomazzi, M., & Borisch, B. (2021) · Epidemiologia · doi:10.3390/epidemiologia2040036 · Cited by 2
Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy
Hamad, M., AlKhamach, D. M. H., Alsayadi, L. M., Sarhan, S. A., Saeed, B. Q., Sokóvić, M., Hadda, T. B., & Soliman, S. S. M. (2023) · Viral Immunology · doi:10.1089/vim.2022.0122 · Cited by 2
Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model
Jeong, J. H., Lee, W. H., Min, S. C., Kim, B. K., Park, O. B., Chokkakula, S., Ahn, S. J., Oh, S., Park, J., Jung, J. W., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119579 · Cited by 2
First detection of SARS‐CoV‐2 BA.2.86.1 in Italy
Caccuri, F., Messali, S., Scarpa, F., Giovanetti, M., Ciccozzi, M., & Caruso, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29175 · Cited by 2
Comparative Atlas of SARS-CoV-2 Substitution Mutations: A Focus on Iranian Strains Amidst Global Trends
Abbasian, M. H., Rahimian, K., Mahmanzar, M., Bayat, S., Kuehu, D. L., Sisakht, M. M., Moradi, B., & Deng, Y. (2024) · Viruses · doi:10.3390/v16081331 · Cited by 2
Virtual Screening and Molecular Simulation Uncover Potent Traditional Chinese Medicine Small Molecules Against SARS‐CoV‐2 M pro
Han, D., Yang, H., Gao, Y., Xue, Y., Liu, F., Wang, M., Lu, J., Liu, T., & Xu, Y. (2025) · ChemistrySelect · doi:10.1002/slct.202405037 · Cited by 2
The impact of viral evolution on vaccine development for SARS-CoV-2
Bachmann, M. F., Mohsen, M. O., & Speiser, D. E. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102612 · Cited by 3
COVID-19: Risk Analysis in South Asia with Respect to Europe and North America
Wadud, M. A. H., Mridha, F., & Nur, K. M. (2021) · AIUB Journal of Science and Engineering (AJSE) · doi:10.53799/ajse.v20i3.196 · Cited by 2
The Biological Properties of the SARS-CoV-2 Cameroon Variant Spike: An Intermediate between the Alpha and Delta Variants
Pascarella, S., Bianchi, M., Giovanetti, M., Benvenuto, D., Borsetti, A., Cauda, R., Cassone, A., & Ciccozzi, M. (2022) · Pathogens · doi:10.3390/pathogens11070814 · Cited by 2
Two-years antibody responses following SARS-CoV-2 infection in humans: A study protocol
Arguni, E., Dewi, F. S. T., Fachiroh, J., Paramita, D. K., Lestari, S. K., Wiratama, B. S., Susilaningrum, A. R., Kharisma, B., Meisyarah, Y. H., Sari, M. P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272690 · Cited by 2
Efficient SARS-CoV-2 Surveillance during the Pandemic-Endemic Transition Using PCR-Based Genotyping Assays
Koets, L., van Leeuwen, K., Derlagen, M., van Wijk, J., Keijzer, N. C. H., Feenstra, J. D. M., Gandhi, M., Sorel, O., van de Laar, T. J. W., & Koppelman, M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03450-22 · Cited by 2
Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS-CoV-2 in the early phase after transplantation
Glueck, O., Liang, X., Badell, I., Wratil, P. R., Graf, A., Krebs, S., Blum, H., Hellmuth, J. C., Scherer, C., Hollaus, A., et al. (2023) · Infection · doi:10.1007/s15010-023-02116-6 · Cited by 2

Authors: Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Kleiner, G., Jurczyszak, D., Matthews, J. C., Mendez, W. A., Mulder, L. C. F., Russo, K. T., Salimbangon, A.-B. T., Saksena, M., Shin, A. S., Sominsky, L. A., Srivastava, K., Krammer, F., Simon, V., Martinez-Sobrido, L., García-Sastre, A., & Schotsaert, M.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Texas Biomedical Research Institute (US)
Tisch Cancer Institute (US)
Corresponding author: Schotsaert, Michael
ORCID: Jangra, Sonia
Ye, Chengjin
Rathnasinghe, Raveen
Stadlbauer, Daniel
Alshammary, Hala
Amoako, Angela A.
Beach, Katherine F
Bermúdez-González, Maria C.
Chernet, Rachel L.
Ferreri, Emily D.
Gleason, Charles R.
Kleiner, Giulio
Jurczyszak, Denise
Mulder, Lubbertus C.F.
Saksena, Miti
Sominsky, Levy A.
Krammer, Florian
Simon, Viviana
Schotsaert, Michael
Venue: The Lancet Microbe
Publisher: Elsevier BV
Published: 2021-07
Volume: 2
Issue: 7
Pages: e283-e284
ISSN: 2666-5247 (ISSN-L)
DOI: 10.1016/s2666-5247(21)00068-9
PMC: PMC8026167
OpenAlex: W3142966103
Cited by: 385
References: 8
Citations by year: 2026: 7 · 2025: 22 · 2024: 35 · 2023: 55 · 2022: 144 · 2021: 121
FWCI: 28.11
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: The Lancet Microbe (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
ImmPort
Funders: JPB Foundation (2020\u2013215611)
U.S. Department of Health and Human Services (HHSN272201400005C)
NCI (U54CA260560)
National Institutes of Health
Pfizer
NIAID (75N93019C00051, HHSN272201400005C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, spike protein, E484K mutation, antibody neutralization, antibody escape, receptor binding domain, Omicron variant, Beta variant, P.1 lineage, convalescent sera, vaccine-induced antibodies
MeSH terms: COVID-19, SARS-CoV-2, Humans, Mutation, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks